<?xml version="1.0" encoding="UTF-8"?>
<funding-group>
 <award-group id="award001">
  <funding-source>
   <institution-wrap>
    <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009947</institution-id>
    <institution>Merck Sharpe &amp; Dohme</institution>
   </institution-wrap>
  </funding-source>
  <award-id>MISP IIS#54846</award-id>
  <principal-award-recipient>
   <name>
    <surname>Valencia La Rosa</surname>
    <given-names>Jorge</given-names>
   </name>
  </principal-award-recipient>
 </award-group>
 <funding-statement>JV has received research grants and honoraria for lectures from Gilead Sciences and travel grants from Gilead Sciences, ViiV, Merck and Janssen; SM has been involved in speaking activities and has received grants for research from Abbott, Boehringer&amp;Ingelheim, Bristol-Myers Squibb, Gilead, Glaxo Smith Kline, Janssen Cilag, Merck Sharp&amp;Dohme, Pfizer, Roche, and Schering Plough.; JT has received honoraria for talks from Gilead and Merck; PR has received grant/research support from Merck, Gilead, Janssen, AbbVie and ViiV. Other authors declare that they have no conflicts of interest.</funding-statement>
</funding-group>
